Houston, TX, December 31, 2021— Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.
With the company’s headquarters in Beijing, China and subsidiaries in Suzhou (China), Taizhou (China), Frankfurt (Germany), and Wayne (Pennsylvania, US), Sino Biological further broadens its worldwide physical presence with the addition of the Houston office. This strategic location allows for direct access via a close proximity to local Texas- and central-US-based pharmaceutical and biotechnology companies as well as the world-renowned Texas Medical Center. The new Houston-based site is located on 10101 Southwest Fwy, Suite 375, and will have its official opening date on the 3rd of January 2022 and will focus on marketing and sales efforts in the region.
“Texas is at the forefront of drug discovery and diagnostic development and leads the world in breakthrough research discoveries. Our new strategic location in Houston will provide invaluable access to key players and clients in the pharmaceutical, biotechnology and basic research sectors. As a native Texan and native Houstonian, I could not be more pleased with the addition of this site to Sino Biological’s worldwide presence”, stated Rob Burgess, Ph.D., Sino Biological’s Chief Business Officer.
Sino Biological is committed to being a designated one-stop gateway for research needs and, with the introduction of the new Houston location, companies and academic as well as medical researchers will have direct access to the Sino Biological team and the company’s comprehensive offering of bioreagents and CRO services.